Critical Warnings & Restrictions

Basic Daonil Information

• INN (International Nonproprietary Name): Glyburide (also known as glibenclamide in several international markets).
• Brand Names Available In United Kingdom: not specified.
• ATC Code: A10BB09.
• Forms & Dosages: Tablets 1.25 mg, 2.5 mg, 5 mg; oral use only; no creams or parenteral forms marketed.
• Manufacturers In United Kingdom: not specified; global manufacturers include Mylan, Teva, Sandoz and regional suppliers.
• Registration Status In United Kingdom: not specified.
• OTC / Rx Classification: Prescription only (POM) in nearly all global markets; not sold over the counter.

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Who worries most about Daonil and why?

Glyburide can cause prolonged and severe hypoglycaemia, so patient safety is the priority before starting treatment.

• Absolute Contraindications (checklist):
  • Type 1 diabetes.
  • Diabetic ketoacidosis (DKA).
  • Known hypersensitivity to glyburide or other sulfonylureas.
  • Significant renal impairment.
  • Significant hepatic impairment.
  • Pregnancy and breastfeeding.
• High‑Risk Groups:
  • Older adults — increased sensitivity to hypoglycaemia; start at the lowest dose available (for example 1.25 mg) and monitor closely.
  • Patients with renal impairment — avoid if impairment is significant.
  • Patients with liver disease — use lower starting doses and monitor liver function and blood glucose.
  • People with G6PD deficiency — risk of haemolysis.
  • Patients with malnutrition or irregular calorie intake.
  • Those with adrenal or pituitary insufficiency.
• Safety Actions (checklist):
  • Confirm recent renal and liver function tests before initiation.
  • Document pregnancy status in women of childbearing potential before prescribing.
  • Ensure informed consent discussing the risk of hypoglycaemia.
  • Provide a written hypoglycaemia action plan at dispense.
  • Recommend MedicAlert or ID card showing diabetes and current treatment.

Interaction With Activities (Driving, Workplace Safety Under UK Law)

Can Daonil affect your ability to drive or operate machinery?

Glyburide (also known as glibenclamide) can cause severe hypoglycaemia that impairs concentration, reaction time and consciousness and therefore affects driving and machine operation.

Under UK Driver and Vehicle Licensing Agency (DVLA) guidance, recurrent or severe hypoglycaemia must be discussed with the treating clinician and may trigger driving restrictions.

• Test blood glucose before driving and at regular intervals on long journeys.
• Avoid driving if blood glucose is under 5 mmol/L or if symptoms of hypoglycaemia are present.
• Always carry fast‑acting carbohydrate (glucose tablets or juice) and a glucagon kit if prescribed.
• If you have a safety‑critical job, inform your employer and follow occupational health advice.
• Discuss any episode of severe or unexplained hypoglycaemia with your diabetes team promptly; you may need to notify the DVLA according to their current rules.

Q&A — “Can I Drive After Taking It In The UK?”

Q: Can I drive after taking glyburide/Daonil?

A: Only if you have no history of severe or recurrent hypoglycaemia, you check your blood glucose before driving and it is safe, and you follow DVLA and clinician guidance.

A: If you experience severe or unexplained hypoglycaemia you must notify your clinician and you may need to inform the DVLA.

Usage Basics

INN, Brand Names Available In The UK

What is Daonil called and what forms does it come in?

The International Nonproprietary Name (INN) is glyburide, which is also marketed as glibenclamide in many countries.

Common international brand names include Micronase, Diabeta and Glynase in historical US usage, and Glycron and various generics in other markets.

Daonil is a recognised brand name for glibenclamide in some international markets, but specific UK brand listings are not specified in the available data.

Formulations are oral tablets typically in 1.25 mg, 2.5 mg and 5 mg strengths.

Legal Classification (POM, P, GSL)

Is a prescription needed to get Daonil in the UK?

Glyburide/glibenclamide is a prescription‑only medicine (POM) across the UK.

Supply must be via an NHS prescription or a private prescription in the United Kingdom.

• Electronic prescribing and NHS e‑prescriptions are widely used for POM medicines.
• Pharmacists will routinely provide counselling at the point of dispense and will check the Summary of Product Characteristics (SPC) or the MHRA for brand‑specific licence details.

Dosing Guide

Standard Regimens (NHS Approach)

How is glyburide usually started and adjusted?

Typical initiation is a low starting dose, commonly 2.5–5 mg once daily with clinical review.

Maintenance doses may range from 1.25 mg to 20 mg per day given as a single dose or divided doses according to response.

The maximum recommended dose is 20 mg per day.

• Take with breakfast or the main meal to reduce the risk of hypoglycaemia.
• Once‑daily dosing is common, but some people are given divided doses to tailor effect and reduce peaks.
• Titration is guided by blood glucose monitoring and HbA1c targets set by the diabetes team.

Adjustments For Comorbidities

Who needs dose changes or extra monitoring?

• Elderly patients — start at the lowest available dose (for example 1.25 mg) and monitor frequently for hypoglycaemia.
• Renal impairment — avoid if impairment is significant; seek specialist advice before use.
• Liver impairment — start lower, titrate slowly and monitor blood glucose and liver function.

Q&A — “What If I Miss A Dose?”

Q: What should I do if I miss a dose?

A: Take the missed dose as soon as you remember unless the next dose is due soon.

A: Do not double up doses to make up for a missed tablet.

A: If in doubt, contact your pharmacist or diabetes team for guidance.

Interaction Chart

Food And Drinks

Which foods and drinks change how glyburide works?

Common Drug Conflicts (Flag Via MHRA Yellow Card)

Which medicines interact with glyburide?

• Drugs that potentiate hypoglycaemia include other glucose‑lowering medicines and some antibiotics such as sulfonamides.
• Certain NSAIDs and other interacting drugs may increase hypoglycaemia risk; check the SPC for specific interactions.
• Warfarin interactions are possible; monitor INR when starting or stopping glyburide.
• Beta‑blockers can mask typical hypoglycaemia warning symptoms such as tremor and tachycardia.
• Report suspected adverse interactions via the MHRA Yellow Card scheme.

User Reports & Trends (Patient Experience Insight)

What do patients commonly say online about glyburide/Daonil?

Typical sources include NHS Choices, Patient.info and various patient forums and parenting sites.

• Common themes are concerns about hypoglycaemia and its impact on daily life.
• Weight gain is frequently reported as a worry or observed side effect.
• Patients often compare older sulfonylureas with metformin and newer agents when discussing efficacy and safety.
• Queries about brand names such as Micronase or Daonil and the availability of generics are common.
• Many people comment favourably on the simplicity of once‑daily dosing when it suits their routine.

How can this patient insight inform pharmacy content?

• Provide a clear, written hypoglycaemia action plan and a simple dosing schedule at dispense.
• Offer pharmacist reassurance about monitoring and alternatives, including gliclazide or metformin combinations.
• Display anonymised patient vignettes and sentiment summaries to help new patients set realistic expectations.

Access & Purchase Options (NHS & Retail Pharmacy Landscape)

High‑Street Chains And Local Pharmacies

Where can glyburide be dispensed in the UK?

Major high‑street pharmacy chains such as Boots, LloydsPharmacy and Superdrug, together with independent pharmacies, dispense medicines on NHS prescriptions.

Pharmacists provide counselling and can offer repeat dispense services where appropriate.

• Bring your repeat prescription or prescription slip to the pharmacy.
• Carry a current medication list and ask for counselling on hypoglycaemia, interactions and storage.

Online Pharmacies And NHS E‑Prescriptions

Can you order glyburide online in the UK?

NHS e‑prescriptions allow nominated collection at a local pharmacy or home delivery through accredited online pharmacy services.

• Confirm the online pharmacy is registered with the General Pharmaceutical Council (GPhC) before ordering.
• Check authenticity of packaging and the patient information leaflet on receipt.
• In our online pharmacy, daonil is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism & Pharmacology

Simplified Explanation

How does glyburide lower blood glucose?

Glyburide stimulates the pancreas to release insulin by closing ATP‑sensitive potassium channels on pancreatic beta cells.

Increased insulin release lowers blood glucose levels but can also cause hypoglycaemia, especially if meals are missed or doses are too high.

Clinical/Pharmacological Terms

• ATC Code: A10BB09, classifying glyburide as a second‑generation sulfonylurea.
• Onset and Duration: Glyburide is a longer‑acting sulfonylurea with sustained insulin secretagogue effect, which increases the risk of prolonged hypoglycaemia.
• Pharmacological Note: Risk of prolonged hypoglycaemia is greater in older adults and those with renal impairment.

A simple diagram of beta‑cell K+ channel action and insulin release is useful for patient education at clinic or pharmacy visits.

Indications & Off‑Label Uses

MHRA‑Approved Uses

What is glyburide licensed for?

The primary indication is treatment of type 2 diabetes mellitus for glycaemic control when appropriate.

Glyburide is typically considered when oral therapy with other agents is indicated or as an add‑on to metformin depending on individual factors.

Absolute exclusions include type 1 diabetes and diabetic ketoacidosis.

Off‑Label Practices In NHS And Private Care

Are there specialist or off‑label uses?

• Occasional specialist uses exist, for example in rare neonatal diabetes under specialist endocrinology supervision, but such use requires careful documentation and informed consent.
• Any off‑label use should be overseen by a specialist and fully documented in clinical notes with the patient's consent.

Key Clinical Findings (UK/EU Evidence Summary)

How does glyburide compare with other diabetes medicines in clinical practice?

• Older sulfonylureas such as glyburide are effective at lowering HbA1c but carry a higher risk of hypoglycaemia versus metformin and many newer agents.
• Caution is advised in elderly patients and those with renal impairment due to the potential for prolonged hypoglycaemia.
• Individualise therapy considering cardiovascular and renal comorbidities and the patient's ability to detect and manage hypoglycaemia.

Clinicians should review HbA1c targets, consider deprescribing if harms outweigh benefit, and document regular monitoring plans.

Alternatives Matrix

NHS Prescribing Alternatives

Pros And Cons Checklist

• Discuss efficacy versus hypoglycaemia risk when choosing therapy.
• Consider weight effects, renal function and monitoring needs.
• Factor in cost and patient preference when selecting an alternative.

Common Patient Questions (Triaged For UK Clinics)

Will it make me gain weight?

Glyburide can cause modest weight gain; discuss diet and exercise and consider alternatives if weight gain is a concern.

How quickly does it work?

Blood glucose can fall within days, with HbA1c improvements seen over weeks to months as dose and adherence are optimised.

Can I take it with metformin?

Yes, glyburide is often used as an add‑on to metformin; start low and titrate with monitoring.

Is it safe in older people?

Older people are at increased risk of hypoglycaemia; start very low, monitor frequently and consider safer alternatives.

Suggested web layout: use expandable FAQ accordions to make these answers easy to browse.

NHS Cost & Access Comparison

How much will it cost and what regional differences matter?

Practical tip: patients on multiple medicines may benefit from an NHS Prepayment Certificate or checking exemption status with NHS services.

Registration & Regulation

MHRA Approval Process And Reporting

Who regulates glyburide in the UK?

Glyburide/glibenclamide is subject to licensing and regulation by the MHRA; prescribers and pharmacists should consult the relevant SPC and patient information leaflet for brand‑specific details.

Report any suspected adverse drug reactions through the MHRA Yellow Card scheme online or via the Yellow Card app.

NHS Prescribing Framework

• Confirm the product licence and document the indication in clinical records.
• Obtain baseline renal and liver tests before initiation.
• Counsel on hypoglycaemia risk and provide written instructions and follow‑up plans.
• Schedule periodic blood glucose and HbA1c monitoring and review therapy annually or when clinical status changes.

Storage & Handling (Practical UK Household Guidance)

UK Household Storage (Cold/Damp Climate)

How should Daonil be stored at home?

• Store tablets at 20–25°C (68–77°F).
• Protect from moisture by keeping in original packaging; avoid bathrooms and windowsills where damp and temperature changes are common in the UK.
• Avoid exposure to extreme heat and direct sunlight.

Travel And Disposal

• Carry medicines in the labelled container and bring a copy of the prescription when travelling.
• Return unused or expired medication to a pharmacy for safe disposal via the household medicines return service.
• If tablets discolour or packaging is damaged, consult the pharmacist before use.

Pharmacists should remind patients to keep medication out of the reach of children and to know what to do in an emergency hypoglycaemia situation.

Guidelines For Proper Use (Practical Patient Safety Checklist)

UK Pharmacist Counselling Style

• Confirm the indication, current dosing and timing at every dispense.
• Review other medicines, including OTC products and alcohol intake, to check for interactions.
• Provide a written hypoglycaemia action plan and explain the symptoms and treatment of low blood sugar.
• Advise on driving and workplace safety in line with DVLA guidance.
• Explain missed‑dose and overdose steps and provide or signpost emergency contact numbers.
• Supply the POM patient information leaflet with each prescription.

NHS Patient Safety Advice (Ongoing Care)

• Keep a record of blood glucose meter readings and bring them to clinic reviews.
• Always carry fast‑acting carbohydrate and wear medical identification if you are taking insulin secretagogues.
• Arrange regular HbA1c and renal monitoring as advised by the diabetes team.
• Review therapy at least annually or when health status changes, and consider deprescribing when risk outweighs benefit.

Suggested downloadable assets for clinics and pharmacies include a printable hypoglycaemia action card, a medication checklist and a local clinic contact sheet.

Delivery Across United Kingdom

Final Notes And Practical Takeaways

Glyburide (glibenclamide) is an established second‑generation sulfonylurea effective at lowering blood glucose but carrying a notable risk of hypoglycaemia, particularly in older adults and those with renal or hepatic impairment.

Prescribers should confirm baseline renal and liver function, document pregnancy status, and provide a clear hypoglycaemia action plan before initiation.

Pharmacists should reinforce safety messages at every dispense, check interactions and advise on driving in line with DVLA guidance.

Consider alternatives such as metformin or newer incretin‑based agents for patients at higher hypoglycaemia risk or with multiple comorbidities.

If patients have questions about brand names such as Micronase, Daonil or generic glibenclamide tablets, signpost them to the SPC or ask them to bring packaging to the pharmacy for verification.

Always report suspected adverse reactions or interactions through the MHRA Yellow Card scheme and consult the SPC for brand‑specific details.